Solve Therapeutics closed a $120 million financing to advance its antibody‑drug conjugate (ADC) platform focused on novel linkers aimed at improving therapeutic index and stability. The company, founded by former VelosBio team members, says its chemistry is designed to overcome limitations that hampered earlier ADC generations. Investors include strategic and crossover backers; Solve plans to deploy capital into lead ADC programs and CMC scale‑up to move candidates deeper into the clinic. The raise underscores sustained investor interest in ADC engineering to expand solid‑tumor indications.